Skip to main content

Table 1 Incremental costs, quality of life and cost-effectiveness ratios in the disease subgroups and in the whole study group

From: Cost-effectiveness analysis for a tele-based health coaching program for chronic disease in primary care

 

Costs (€), mean (95% CI)

QoL (15D), mean (95% CI)

ICER (€/QALY)

 

Intervention

Control

Incremental cost

Intervention

Control

Incremental effect

 

Type 2 diabetes

1948 (1673–2222)

1788 (1204–2371)

160 (−406–726)

0.008 (0.003– 0.014)

0.000 (−0.009–0.009)

0.008 (−0.002–0.018)

20 000

Coronary artery disease

2510 (1806–3214)

1785 (984–2585)

725 (−389–1839)

0.019 (0.007–0.030)

0.001 (−0.014–0.016)

0.018 (−0.001–0.037)

40 278

Congestive heart failure

4469 (1955–6983)

2214 (−105–4533)

2255 (−1669–6180)

0.013 (−0.007–0.032)

0.015 (−0.015–0.046)

−0.003 (−0.037–0.032

-

All

2256 (1940–2571)

1824 (1345–2302)

432 (−135–999)

0.011 (0.006 − 0.015)

0.002 (−0.006–0.009)

0.009 (0.000–0.018)

48 000

  1. CI confidence interval, QoL Quality of Life, ICER incremental cost-effectiveness ratio, QALY quality- adjusted life years